Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-24-076599
Filing Date
2024-09-06
Accepted
2024-09-06 17:08:49
Documents
3
Group Members
FAIRMOUNT HEALTHCARE CO-INVEST III L.P.;FAIRMOUNT HEALTHCARE FUND II L.P.;PETER HARWIN;TOMAS KISELAK

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea0213742-13dfair_oruka.htm SC 13D 142353
2 JOINT FILING AGREEMENT ea021374201ex99-1_oruka.htm EX-99.1 8162
3 FORM OF REGISTRATION RIGHTS AGREEMENT, BY AND AMONG THE COMPANY, PRE-MERGER ORUK ea021374201ex99-4_oruka.htm EX-99.4 108139
  Complete submission text file 0001213900-24-076599.txt   260732
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-51477 | Film No.: 241285191
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

EIN.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D